Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Tollys
company
About
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €2.30M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company is advancing TL-532, a new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€2.30M
Tollys has raised a total of
€2.30M
in funding over 2 rounds. Their latest funding was raised on
May 26, 2020 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 26, 2020 | Series A | €2.30M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Tollys is funded by 1 investors.
Investisseurs privés
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
